Project TitleSmall Molecule for Treatment of Epilepsy, Pain, and Other Neurological Disorders
Track Code2007-036
Short Description

A new class of small molecules that may be used to target specific AMPA* receptors

#therapeutics #smallmolecules #pain #neurology


Over-activation of AMPA receptors contributes to the pathology of a number of neurological diseases, particularly epilepsy, neuropathic pain, and stroke. A new group of heterotricyclic molecules called "IKM" analogs have been determined to act pharmacologically as AMPA receptor antagonists. Northwestern researchers have discovered a new class of small molecules that may be used to target specific AMPA receptors. A small molecule, 2,4-epi-neodysiherbaine (2,4-epi-NDH), has been determined to act as a selective kainate receptor antagonist. 2,4-epi-NDH is a synthetic analog of a natural molecule, dysiherbaine, which is itself a rigid analog of the excitatory amino acid neurotransmitter L-glutamate. The novelty of 2,4-epi-NDH is structural in that it has altered stereochemistry at the C2 and C4 positions and thus is not strictly considered an L-glutamate congener. The molecular also exhibits a novel pharmacological profile. There currently is no commercially available small molecule with similar pharmacological activity, making 2,4-epi-neodysiherbaine a desirable candidate for therapeutic use.

Posted DateMar 3, 2011 10:44 AM


Leanne Lash
Geoffrey Swanson*

Ryuichi Sakai


• Small molecule therapy for epilepsy, pain, and stroke


• Selective antagonist for kainite receptor

• No other commercially available molecule with similar activity

IP Status

Issued US Patent No. 7,973,075

Marketing Contact

Michael Moore, PhD
Invention Manager  

(p) 847.491.4645